{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T04:13:48Z","timestamp":1771992828029,"version":"3.50.1"},"reference-count":152,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,11]]},"DOI":"10.1093\/eurheartj\/ehaa1061","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T20:13:30Z","timestamp":1608668010000},"page":"657-670","source":"Crossref","is-referenced-by-count":34,"title":["The year in cardiovascular medicine 2020: heart failure and cardiomyopathies"],"prefix":"10.1093","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0277-7596","authenticated-orcid":false,"given":"H\u00e9ctor","family":"Bueno","sequence":"first","affiliation":[{"name":"Multidisciplinary Translational Cardiovascular Research Group. Centro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fern\u00e1ndez Almagro , 3, Madrid 28029, Spain"},{"name":"Cardiology Department, Hospital Universitario 12 de Octubre and Instituto de Investigaci\u00f3n Sanitaria Hospital , 12 de Octubre (imas12), Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Cardiovaculares (CIBERCV) , Madrid, Spain"},{"name":"Facultad de Medicina, Universidad Complutense de Madrid, Plaza de Ram\u00f3n y Cajal , s\/n, 28040 Madrid, Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6158-7368","authenticated-orcid":false,"given":"Brenda","family":"Moura","sequence":"additional","affiliation":[{"name":"Cardiology Department, Military Hospital, Av. da Boavista S\/N , 4050-115 Porto, Portugal"},{"name":"CINTESIS\u2014Center for Health Technology and Services Research , R. Dr. Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0804-8194","authenticated-orcid":false,"given":"Patrizio","family":"Lancellotti","sequence":"additional","affiliation":[{"name":"Department of Cardiology, CHU SartTilman, University of Li\u00e8ge Hospital, GIGA Cardiovascular Sciences, Avenue de L'H\u00f4pital 1 , 4000 Li\u00e8ge, Belgium"},{"name":"Cardiology Departments, Gruppo Villa Maria Care and Research, Maria Cecilia Hospital , Cotignola Bari, Italy and Via Corriera, 1, 48033 Cotignola RA, Italy and Anthea Hospital, Via Camillo Rosalba, 35\/37, 70124 Bari BA, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9341-117X","authenticated-orcid":false,"given":"Johann","family":"Bauersachs","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, Hannover Medical School , Carl-Neuberg-Str. 1, 30625 Hannover, Germany"}]}],"member":"286","published-online":{"date-parts":[[2021,1,3]]},"reference":[{"key":"2022102612135132500_ehaa1061-B1","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ejhf.1609","article-title":"Heart failure in Norway, 2000-2014: analysing incident, total and readmission rates using data from the Cardiovascular Disease in Norway (CVDNOR) Project","volume":"22","author":"Sulo","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B3","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/ejhf.1350","article-title":"Risk factors for incident heart failure in age- and sex-specific strata: a population-based cohort using linked electronic health records","volume":"21","author":"Uijl","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B4","doi-asserted-by":"crossref","first-page":"e841\u201363","DOI":"10.1161\/CIR.0000000000000767","article-title":"Addressing social determinants of health in the care of patients with heart failure: a scientific statement from the American Heart Association","volume":"141","author":"White-Williams","year":"2020","journal-title":"Circulation"},{"key":"2022102612135132500_ehaa1061-B5","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/ejhf.1918","article-title":"Clinical course after a first episode of heart failure: insights from the Framingham Heart Study","volume":"22","author":"Velagaleti","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B6","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1093\/eurheartj\/ehz584","article-title":"Incidence of heart failure after pacemaker implantation: a nationwide Danish Registry-based follow-up study","volume":"40","author":"Tayal","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102612135132500_ehaa1061-B7","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1093\/eurheartj\/ehz773","article-title":"Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review","volume":"41","author":"Barra","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102612135132500_ehaa1061-B8","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/eurheartj\/ehaa071","article-title":"The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions","volume":"41","author":"Motiej\u016bnait\u0117","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102612135132500_ehaa1061-B9","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jamacardio.2020.2028","article-title":"Trends in readmission and mortality rates following heart failure hospitalization in the Veterans Affairs Health Care System from 2007 to 2017","volume":"5","author":"Parizo","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2022102612135132500_ehaa1061-B10","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/ejhf.1800","article-title":"Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort","volume":"22","author":"Butt","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/ejhf.1721","article-title":"The recurring problem of heart failure hospitalisations","volume":"22","author":"Jhund","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ejhf.1678","article-title":"Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"\u010celutkien\u0117","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B13","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1161\/CIRCULATIONAHA.119.043964","article-title":"OUTSMART HF: a randomized controlled trial of routine versus selective cardiac magnetic resonance for patients with nonischemic heart failure (IMAGE-HF 1B)","volume":"141","author":"Paterson","year":"2020","journal-title":"Circulation"},{"key":"2022102612135132500_ehaa1061-B14","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/ejhf.1961","article-title":"Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities","volume":"22","author":"Quarta","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B15","doi-asserted-by":"publisher","DOI":"10.1016\/j","article-title":"Imaging interstitial fibrosis, left ventricular remodeling, and function in stage A and B heart failure","author":"Pezel","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2022102612135132500_ehaa1061-B16","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/ehf2.12830","article-title":"T1 and T2 mapping to detect chronic inflammation in cardiac magnetic resonance imaging in heart failure with reduced ejection fraction","volume":"7","author":"Emrich","year":"2020","journal-title":"ESC Hear Fail"},{"key":"2022102612135132500_ehaa1061-B17","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jcmg.2019.02.031","article-title":"CMR in the evaluation of diastolic dysfunction and phenotyping of HFpEF: current role and future perspectives","volume":"13","author":"Chamsi-Pasha","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2022102612135132500_ehaa1061-B18","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeaa041(accessed","article-title":"Left atrial remodelling, mid-regional pro-atrial natriuretic peptide, and prognosis across a range of ejection fractions in heart failure","author":"Putko","year":"2020","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2022102612135132500_ehaa1061-B19","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jacc.2020.06.069","article-title":"Pulmonary hypertension in HFpEF and HFrEF: JACC review topic of the week","volume":"76","author":"Guazzi","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102612135132500_ehaa1061-B20","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s00330-019-06261-1","article-title":"Application of the newest European Association of Cardiovascular Imaging Recommendation regarding the long-term prognostic relevance of left ventricular diastolic function in heart failure with preserved ejection fraction","volume":"30","author":"Lin","year":"2020","journal-title":"Eur Radiol"},{"key":"2022102612135132500_ehaa1061-B21","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/ehf2.12748","article-title":"Echocardiography to estimate high filling pressure in patients with heart failure and reduced ejection fraction","volume":"7","author":"Romano","year":"2020","journal-title":"ESC Hear Fail"},{"key":"2022102612135132500_ehaa1061-B22","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1002\/ehf2.12826","article-title":"Multilayer myocardial strain improves the diagnosis of heart failure with preserved ejection fraction","volume":"7","author":"Tanacli","year":"2020","journal-title":"ESC Hear Fail"},{"key":"2022102612135132500_ehaa1061-B23","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jchf.2020.03.013","article-title":"Application of diagnostic algorithms for heart failure with preserved ejection fraction to the community","volume":"8","author":"Selvaraj","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2022102612135132500_ehaa1061-B24","doi-asserted-by":"crossref","first-page":"e001112","DOI":"10.1136\/openhrt-2019-001112","article-title":"Prognostic impacts of changes in left ventricular ejection fraction in heart failure patients with preserved left ventricular ejection fraction","volume":"7","author":"Yoshihisa","year":"2020","journal-title":"Open Heart"},{"key":"2022102612135132500_ehaa1061-B25","article-title":"Incremental prognostic value of global myocardial work over ejection fraction and global longitudinal strain in patients with heart failure and reduced ejection fraction","author":"Wang","year":"2020","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2022102612135132500_ehaa1061-B26","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/ehf2.12656","article-title":"Short-term echocardiographic evaluation by global longitudinal strain in patients with heart failure treated with sacubitril\/valsartan","volume":"7","author":"Mazzetti","year":"2020","journal-title":"ESC Hear Fail"},{"key":"2022102612135132500_ehaa1061-B27","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1093\/eurheartj\/ehaa191","article-title":"Hypertensive coronary microvascular dysfunction: a subclinical marker of end organ damage and heart failure","volume":"41","author":"Zhou","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102612135132500_ehaa1061-B28","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1093\/eurheartj\/ehaa437","article-title":"Coronary microcirculation and hypertensive heart failure","volume":"41","author":"Escaned","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102612135132500_ehaa1061-B29","article-title":"Prognostic significance of cardiac I-123-metaiodobenzylguanidine imaging in patients with reduced, mid-range, and preserved left ventricular ejection fraction admitted for acute decompensated heart failure: a prospective study in Osaka Prefectural Acute","author":"Seo","year":"2020","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2022102612135132500_ehaa1061-B30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jacc.2020.05.072","article-title":"Effect of sacubitril\/valsartan on biomarkers of extracellular matrix regulation in patients with HFpEF","volume":"76","author":"Cunningham","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102612135132500_ehaa1061-B31","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/ejhf.1701","article-title":"Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T","volume":"22","author":"Aimo","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B32","article-title":"Differences in biomarkers and molecular pathways according to age for patients with HFrEF","author":"Ferreira","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2022102612135132500_ehaa1061-B33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/ejhf.1667","article-title":"Improve management of acute heart failure with ProcAlCiTonin in EUrope: results of the randomized clinical trial IMPACT\u2009EU Biomarkers in Cardiology (BIC) 18","volume":"22","author":"M\u00f6ckel","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B34","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1093\/eurheartj\/ehaa270","article-title":"Omics phenotyping in heart failure: the next frontier","volume":"41","author":"Bayes-Genis","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102612135132500_ehaa1061-B35","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1002\/ehf2.12928","article-title":"Incremental prognostic value of a novel metabolite-based biomarker score in congestive heart failure patients","volume":"7","author":"McGranaghan","year":"2020","journal-title":"ESC Hear Fail"},{"key":"2022102612135132500_ehaa1061-B36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"2022102612135132500_ehaa1061-B37","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/eurheartj\/ehaa388","article-title":"Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy","volume":"41","author":"Inciardi","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102612135132500_ehaa1061-B38","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1093\/eurheartj\/ehaa373","article-title":"Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors","volume":"41","author":"Sama","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102612135132500_ehaa1061-B39","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/ejhf.1871","article-title":"COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease","volume":"22","author":"Tomasoni","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B40","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(20)31030-8","article-title":"Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study","volume":"395","author":"de Abajo","year":"2020","journal-title":"Lancet"},{"key":"2022102612135132500_ehaa1061-B41","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/ejhf.1924","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust","volume":"22","author":"Bean","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B42","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","article-title":"Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19","volume":"382","author":"Reynolds","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102612135132500_ehaa1061-B43","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin-angiotensin-aldosterone system blockers and the risk of Covid-19","volume":"382","author":"Mancia","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102612135132500_ehaa1061-B44","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1990","article-title":"Heart failure in Covid-19 patients: prevalence, incidence and prognostic implications","author":"Rey","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B45","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/ejhf.1925","article-title":"The impact of COVID-19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic","volume":"22","author":"Bromage","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B46","doi-asserted-by":"crossref","first-page":"e007274","DOI":"10.1161\/CIRCHEARTFAILURE.120.007274","article-title":"Incidence of new-onset and worsening heart failure before and after the COVID-19 epidemic lockdown in Denmark: a nationwide cohort study","volume":"13","author":"Andersson","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2022102612135132500_ehaa1061-B47","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1986","article-title":"Temporal trends in decompensated heart failure and outcomes during COVID-19: a multisite report from heart failure referral centres in London","author":"Cannata","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B48","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/ejhf.1915","article-title":"Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Zhang","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B49","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/ejhf.1900","article-title":"Experience of remote cardiac care during the COVID-19 pandemic: the V-LAPTM device in advanced heart failure","volume":"22","author":"D'Amario","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B50","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/eurheartj\/ehaa461","article-title":"Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"41","author":"Anker","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102612135132500_ehaa1061-B51","doi-asserted-by":"crossref","first-page":"e006134","DOI":"10.1161\/CIRCHEARTFAILURE.119.006134","article-title":"Sex differences in quality of life and clinical outcomes in patients with advanced heart failure: insights from the PAL-HF trial","volume":"13","author":"Truby","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2022102612135132500_ehaa1061-B52","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/ejhf.1645","article-title":"Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry","volume":"22","author":"Lain\u0161\u010dak","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B53","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/ejhf.1740","article-title":"Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials","volume":"22","author":"Rossello","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B54","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/ejhf.1776","article-title":"Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure","volume":"22","author":"Dewan","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B55","doi-asserted-by":"crossref","first-page":"e006605","DOI":"10.1161\/CIRCHEARTFAILURE.119.006605","article-title":"Representation of women authors in international heart failure guidelines and contemporary clinical trials","volume":"13","author":"Reza","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2022102612135132500_ehaa1061-B56","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/CIRCULATIONAHA.120.047019","article-title":"Temporal trends in prevalence and prognostic implications of comorbidities among patients with acute decompensated heart failure: the ARIC study community surveillance","volume":"142","author":"Pandey","year":"2020","journal-title":"Circulation"},{"key":"2022102612135132500_ehaa1061-B57","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/ejhf.1818","article-title":"Trends in prevalence of comorbidities in heart failure clinical trials","volume":"22","author":"Khan","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B58","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/ejhf.1795","article-title":"The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial\u2014insights from ASCEND-HF","volume":"22","author":"Bhatt","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B59","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/ejhf.1846","article-title":"The unbearable underreporting of comorbidities in heart failure clinical trials","volume":"22","author":"Aimo","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B60","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/ejhf.1682","article-title":"Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction","volume":"22","author":"Docherty","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B61","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1161\/CIRCULATIONAHA.119.045204","article-title":"Advancing research on the complex interrelations between atrial fibrillation and heart failure: a report from a US National Heart, Lung, and Blood Institute Virtual Workshop","volume":"141","author":"Al-Khatib","year":"2020","journal-title":"Circulation"},{"key":"2022102612135132500_ehaa1061-B62","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ejhf.1646","article-title":"Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment","volume":"22","author":"Packer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B63","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/ejhf.1733","article-title":"Heart rate control in heart failure with reduced ejection fraction: the bright and the dark side of the moon","volume":"22","author":"Bauersachs","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B64","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ejhf.1697","article-title":"Evaluation of kidney function throughout the heart failure trajectory\u2014a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Mullens","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B65","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jchf.2019.09.012","article-title":"Diuretic strategies for loop diuretic resistance in acute heart failure: the 3T trial","volume":"8","author":"Cox","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2022102612135132500_ehaa1061-B66","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1002\/ejhf.1743","article-title":"Treatment with 24\u2009hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial","volume":"22","author":"Carubelli","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B67","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/ejhf.1831","article-title":"Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Harjola","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B68","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1177\/2048872619894255","article-title":"Atrial fibrillation in acute heart failure: a position statement from the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology","volume":"9","author":"Gorenek","year":"2020","journal-title":"Eur Hear J Acute Cardiovasc Care"},{"key":"2022102612135132500_ehaa1061-B69","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ejhf.1750","article-title":"Trends in cardiogenic shock complicating acute myocardial infarction","volume":"22","author":"Aissaoui","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B70","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/ccd.29139","article-title":"SCAI shock classification in acute myocardial infarction: insights from the National Cardiogenic Shock Initiative","volume":"96","author":"Hanson","year":"2020","journal-title":"Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv"},{"key":"2022102612135132500_ehaa1061-B71","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/2048872619894254","article-title":"Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: a document of the Acute Cardiovascular Care Association of the European Society of Car","volume":"9","author":"Zeymer","year":"2020","journal-title":"Eur Hear J Acute Cardiovasc Care"},{"key":"2022102612135132500_ehaa1061-B72","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/ejhf.1922","article-title":"Epidemiology, pathophysiology and contemporary management of cardiogenic shock\u2014a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Chioncel","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B73","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ejhf.1773","article-title":"Randomized trial of a left ventricular assist device as destination therapy versus guideline-directed medical therapy in patients with advanced heart failure. Rationale and design of the SWEdish evaluation of left Ventricular Assist Device (SweVAD) trial","volume":"22","author":"Karason","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B74","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijcard.2019.12.027","article-title":"Characteristics and outcomes of pregnant women with cardiomyopathy stratified by etiologies: a population-based study","volume":"305","author":"Phan","year":"2020","journal-title":"Int J Cardiol"},{"key":"2022102612135132500_ehaa1061-B75","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/ejhf.1493","article-title":"Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy","volume":"21","author":"Bauersachs","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B76","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/ejhf.1912","article-title":"The European Society of Cardiology Heart Failure Association Study Group on Peripartum Cardiomyopathy\u2014what has been achieved in 10\u2009years","volume":"22","author":"Sliwa","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B77","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1093\/eurheartj\/ehaa455","article-title":"Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry","volume":"41","author":"Sliwa","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102612135132500_ehaa1061-B78","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jacc.2019.11.014","article-title":"Peripartum cardiomyopathy: JACC state-of-the-art review","volume":"75","author":"Davis","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102612135132500_ehaa1061-B79","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jacc.2020.05.075","article-title":"Heart Failure With recovered left ventricular ejection fraction: JACC Scientific Expert Panel","volume":"76","author":"Wilcox","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102612135132500_ehaa1061-B80","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2022102612135132500_ehaa1061-B81","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/echo.14800","article-title":"Focused echocardiography in cardio-oncology","volume":"37","author":"Keramida","year":"2020","journal-title":"Echocardiography"},{"key":"2022102612135132500_ehaa1061-B82","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jaccao.2020.04.011","article-title":"Magnetic resonance imaging to detect cardiovascular effects of cancer therapy","volume":"2","author":"Harries","year":"2020","journal-title":"JACC CardioOncology"},{"key":"2022102612135132500_ehaa1061-B83","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","article-title":"Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis","volume":"41","author":"Zhang","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102612135132500_ehaa1061-B84","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaccao.2020.02.016","article-title":"Longitudinal changes in echocardiographic parameters of cardiac function in pediatric cancer survivors","volume":"2","author":"Border","year":"2020","journal-title":"JACC CardioOncology"},{"key":"2022102612135132500_ehaa1061-B85","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehaa006","article-title":"Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry","volume":"41","author":"L\u00f3pez-Send\u00f3n","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102612135132500_ehaa1061-B86","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1093\/eurheartj\/ehz713","article-title":"The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction","volume":"40","author":"Reddy","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102612135132500_ehaa1061-B87","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1093\/eurheartj\/ehz626","article-title":"The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction","volume":"40","author":"Obokata","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102612135132500_ehaa1061-B88","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/eurheartj\/ehaa037","article-title":"Aetiology and outcomes of severe right ventricular dysfunction","volume":"41","author":"Padang","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102612135132500_ehaa1061-B89","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cardfail.2019.12.004","article-title":"Baseline right ventricular dysfunction predicts worse outcomes in patients undergoing cardiac resynchronization therapy implantation","volume":"26","author":"Patel","year":"2020","journal-title":"J Card Fail"},{"key":"2022102612135132500_ehaa1061-B90","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jchf.2020.06.015","article-title":"Sacubitril\/valsartan and sudden cardiac death according to implantable cardioverter-defibrillator use and heart failure cause: a PARADIGM-HF analysis","volume":"8","author":"Rohde","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2022102612135132500_ehaa1061-B91","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/ehf2.12659","article-title":"Sacubitril\/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease","volume":"7","author":"Lee","year":"2020","journal-title":"ESC Hear Fail"},{"key":"2022102612135132500_ehaa1061-B92","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jchf.2020.05.005","article-title":"Sacubitril\/valsartan in advanced heart failure with reduced ejection fraction: rationale and design of the lIFE trial","volume":"8","author":"Mann","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2022102612135132500_ehaa1061-B93","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.119.044491","article-title":"Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF","volume":"141","author":"McMurray","year":"2020","journal-title":"Circulation"},{"key":"2022102612135132500_ehaa1061-B94","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jacc.2019.11.003","article-title":"Prior heart failure hospitalization, clinical outcomes, and response to sacubitril\/valsartan compared with valsartan in HFpEF","volume":"75","author":"Vaduganathan","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102612135132500_ehaa1061-B95","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jacc.2020.02.009","article-title":"Systolic blood pressure in heart failure with preserved ejection fraction treated with sacubitril\/valsartan","volume":"75","author":"Selvaraj","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102612135132500_ehaa1061-B96","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.120.047643","article-title":"Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction","volume":"142","author":"Mc Causland","year":"2020","journal-title":"Circulation"},{"key":"2022102612135132500_ehaa1061-B97","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1002\/ejhf.1984","article-title":"Serum uric acid, influence of sacubitril\/valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF","volume":"22","author":"Selvaraj","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B98","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.amjcard.2020.01.009","article-title":"Meta-analysis evaluating the effects of renin-angiotensin-aldosterone system blockade on outcomes of heart failure with preserved ejection fraction","volume":"125","author":"Kuno","year":"2020","journal-title":"Am J Cardiol"},{"key":"2022102612135132500_ehaa1061-B99","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1093\/eurheartj\/ehaa184","article-title":"A putative placebo analysis of the effects of sacubitril\/valsartan in heart failure across the full range of ejection fraction","volume":"41","author":"Vaduganathan","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102612135132500_ehaa1061-B100","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1093\/eurheartj\/ehaa281","article-title":"Ejection fraction in heart failure revisited\u2014where does the evidence start?","volume":"41","author":"B\u00f6hm","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102612135132500_ehaa1061-B101","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/ejhf.1954","article-title":"Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. The position paper of the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Seferovi\u0107","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B102","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ejhf.1673","article-title":"European Society of Cardiology\/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure","volume":"22","author":"Seferovi\u0107","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B103","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102612135132500_ehaa1061-B104","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/CIRCULATIONAHA.120.050255","article-title":"Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial","volume":"142","author":"Cosentino","year":"2020","journal-title":"Circulation"},{"key":"2022102612135132500_ehaa1061-B105","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102612135132500_ehaa1061-B106","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B107","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA"},{"key":"2022102612135132500_ehaa1061-B108","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1093\/eurheartj\/ehaa183","article-title":"Effects of dapagliflozin in DAPA-HF according to background heart failure therapy","volume":"41","author":"Docherty","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102612135132500_ehaa1061-B109","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/CIRCULATIONAHA.119.044133","article-title":"Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF","volume":"141","author":"Martinez","year":"2020","journal-title":"Circulation"},{"key":"2022102612135132500_ehaa1061-B110","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1093\/eurheartj\/ehaa496","article-title":"Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)","volume":"41","author":"Serenelli","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102612135132500_ehaa1061-B111","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF","author":"Jhund","year":"2020","journal-title":"Circulation"},{"key":"2022102612135132500_ehaa1061-B112","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","article-title":"Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial","volume":"141","author":"Kosiborod","year":"2020","journal-title":"Circulation"},{"key":"2022102612135132500_ehaa1061-B113","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/ejhf.1978","article-title":"Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF","volume":"22","author":"McEwan","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B114","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102612135132500_ehaa1061-B115","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102612135132500_ehaa1061-B116","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial","author":"Packer","year":"2020","journal-title":"Circulation"},{"key":"2022102612135132500_ehaa1061-B117","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz553","article-title":"Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial","author":"Packer","year":"2020","journal-title":"Eur Hear J"},{"key":"2022102612135132500_ehaa1061-B118","article-title":"Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status\u2014results from the EMPEROR-Reduced trial","author":"Anker","year":"2020","journal-title":"Circulation"},{"key":"2022102612135132500_ehaa1061-B119","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet (London, England)"},{"key":"2022102612135132500_ehaa1061-B120","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA","article-title":"Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)","author":"Lee","year":"2020","journal-title":"Circulation"},{"key":"2022102612135132500_ehaa1061-B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized trial of empagliflozin in non-diabetic patients with heart failure and reduced ejection fraction","author":"Santos-Gallego","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102612135132500_ehaa1061-B122","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1093\/eurheartj\/ehaa731","article-title":"Totality of evidence in trials of sodium-glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice","volume":"41","author":"Butler","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102612135132500_ehaa1061-B123","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","author":"Bhatt","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102612135132500_ehaa1061-B124","article-title":"Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease","author":"Bhatt","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102612135132500_ehaa1061-B125","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/ejhf.1664","article-title":"Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial","volume":"21","author":"Pieske","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B126","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102612135132500_ehaa1061-B127","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/CIRCULATIONAHA.120.047086","article-title":"Comparing the benefit of novel therapies across clinical trials: insights from the VICTORIA trial","volume":"142","author":"Butler","year":"2020","journal-title":"Circulation"},{"key":"2022102612135132500_ehaa1061-B128","doi-asserted-by":"crossref","first-page":"e005998","DOI":"10.1161\/CIRCHEARTFAILURE.119.005998","article-title":"Rationale and design of the VITALITY-HFpEF trial","volume":"12","author":"Butler","year":"2019","journal-title":"Circ Heart Fail"},{"key":"2022102612135132500_ehaa1061-B129","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jchf.2020.08.008","article-title":"N-terminal Pro-B-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study","volume":"8","author":"Ezekowitz","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2022102612135132500_ehaa1061-B130","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"2022102612135132500_ehaa1061-B131","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ahj.2020.01.009","article-title":"Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved eje","volume":"222","author":"Udelson","year":"2020","journal-title":"Am Heart J"},{"key":"2022102612135132500_ehaa1061-B132","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","author":"Teerlink","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102612135132500_ehaa1061-B133","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/ejhf.1933","article-title":"Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial","volume":"22","author":"Voors","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B134","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2022102612135132500_ehaa1061-B135","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/ejhf.1710","article-title":"Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure","volume":"21","author":"Ponikowski","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B136","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","author":"Ponikowski","year":"2020","journal-title":"Lancet (London, England)"},{"key":"2022102612135132500_ehaa1061-B137","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa791","article-title":"CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure","author":"Batkai","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102612135132500_ehaa1061-B138","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa898","article-title":"Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study","author":"T\u00e4ubel","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102612135132500_ehaa1061-B139","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet (London, England)"},{"key":"2022102612135132500_ehaa1061-B140","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1002\/ejhf.1774","article-title":"The impact of residual mitral regurgitation after MitraClip therapy in functional mitral regurgitation","volume":"22","author":"Reichart","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B141","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.jacc.2020.01.040","article-title":"Withdrawal of neurohumoral blockade after cardiac resynchronization therapy","volume":"75","author":"Nijst","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102612135132500_ehaa1061-B142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2020.05.015","article-title":"Baroreflex activation therapy in patients with heart failure with reduced ejection fraction","volume":"76","author":"Zile","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102612135132500_ehaa1061-B143","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/ejhf.1943","article-title":"Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF)","volume":"22","author":"Angermann","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B144","doi-asserted-by":"crossref","first-page":"e006513","DOI":"10.1161\/CIRCHEARTFAILURE.119.006513","article-title":"Continuous wearable monitoring analytics predict heart failure hospitalization: the LINK-HF multicenter study","volume":"13","author":"Stehlik","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2022102612135132500_ehaa1061-B145","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1136\/heartjnl-2020-316773","article-title":"Home monitoring with technology-supported management in chronic heart failure: a randomised trial","volume":"106","author":"Rahimi","year":"2020","journal-title":"Heart"},{"key":"2022102612135132500_ehaa1061-B146","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/ejhf.1906","article-title":"Telemonitoring versus standard care in heart failure: a randomised multicentre trial","volume":"22","author":"Galinier","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B147","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/ejhf.1709","article-title":"Impact of remote monitoring on clinical outcomes for patients with heart failure and atrial fibrillation: results from the REM-HF trial","volume":"22","author":"Zakeri","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B148","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jchf.2020.06.006","article-title":"Heart failure collaboratory statement on remote monitoring and social distancing in the landscape of COVID-19","volume":"8","author":"Abraham","year":"2020","journal-title":"JACC Heart Failure"},{"key":"2022102612135132500_ehaa1061-B149","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2008","article-title":"Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology","author":"Jaarsma","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B150","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1994","article-title":"Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper","author":"Hill","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102612135132500_ehaa1061-B151","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/cvr\/cvz200","article-title":"Palliative care for people living with heart failure: European Association for Palliative Care Task Force expert position statement","volume":"116","author":"Sobanski","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2022102612135132500_ehaa1061-B152","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.1783","article-title":"The impact of palliative care on clinical and patient-centred outcomes in patients with advanced heart failure: a systematic review of randomized controlled trials","author":"Sahlollbey","year":"2020","journal-title":"Eur J Heart Fail"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/6\/657\/46644320\/ehaa1061.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/6\/657\/46644320\/ehaa1061.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T12:16:33Z","timestamp":1666786593000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/42\/6\/657\/6060054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,3]]},"references-count":152,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,1,3]]},"published-print":{"date-parts":[[2021,2,11]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaa1061","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2,7]]},"published":{"date-parts":[[2021,1,3]]}}}